Cesar Libanati MD. Cesar received his medical degree with honors from the University of Buenos Aires Medical School, Argentina in 1982. He subsequently moved to the US and completed training and diplomacy in internal medicine and geriatrics. His early interest in skeletal metabolism lead to a research fellowship in Dr. David Baylink’s Mineral Metabolism Unit with who he remained associated for over two decades while on medical staff at Loma Linda University and the Veteran Administration. He directed the Osteoporosis Research Center at Loma Linda and his research covered basic, translational and clinical osteoporosis and mineral metabolism with a particular emphasis on bone imaging. He has authored numerous research articles, book chapters and abstracts, is a member of professional skeletal societies and serves as a scientific reviewer in bone journals. In 2005 he joined the Bone Research and Development Group at Amgen, California where he advanced the development, registration and commercialization of denosumab for the treatment of osteoporosis. After 10 years at Amgen he joined UCB in Brussels to continue developing solutions for patients suffering from osteoporosis and fractures; leading to the recent approval of romosozumab for postmenopausal women with severe osteoporosis at high risk of fracture. His current position is Head, Medical External Affairs in the Bone Patient Value Unit at UCB Pharma.
You are here: / Boards / Cesar Libanati